Table 2.

Primary Outcome: VAS scoring of symptoms and the Modified McCormack Pain Scale in the Acacia and the control group.

Primary outcome	Acacia group (n = 33)	Placebo group (n = 33)	p value
VAS for LAP and LBA
Day 0	4.66 ± 1.68	5.18 ± 1.26	0.26
Days 11–14	1.36 ± 1.72	5.06 ± 1.27	<0.0001
Day 45	0.63 ± 1.02a	4.90 ± 1.33b	<0.0001
VAS for abnormal vaginal discharge
Day 0	6.39 ± 0.70	6.12 ± 0.59	0.39
Days 11–14	1.51 ± 2.04	6 ± 0.61	<0.0001
Day 45	0.60 ± 1.19a	6 ± 0.61b	<0.0001
VAS for dyspareunia
Day 0	1.54 ± 2.32	1.75 ± 2.34	0.83
Days 11–14	0.15 ± 0.44	1.72 ± 2.34	0.02
Day 45	0.03 ± 0.17a	1.60 ± 2.20b	0.007
VAS for dysuria
Day 0	1.69 ± 2.43	1.84 ± 2.43	0.74
Days 11–14	1.69 ± 2.43	1.81 ± 2.39	0.04
Day 45	0.09 ± 0.29a	1.66 ± 2.21b	0.008
VAS for burning micturition
Day 0	3.48 ± 2.48	3 ± 2.44	0.38
Days 11–14	0.75 ± 1.03	2.84 ± 2.34	0.0007
Day 45	0.33 ± 0.64a	2.69 ± 2.24b	0.0001
VAS for vulvar irritation
Day 0	3.18 ± 2.55	3 ± 2.72	0.94
Days 11–14	0.87 ± 1.34	2.87 ± 2.64	0.003
Day 45	0.18 ± 0.46a	2.84 ± 2.60b	<0.0001
VAS for vulvar itching
Day 0	4.63 ± 2.14	3.90 ± 2.45	0.18
Days 11–14	1.42 ± 1.73	3.78 ± 2.23	<0.0001
Day 45	0.39 ± 0.65a	3.63 ± 2.35b	<0.0001
Modified McCormack Pain Scale (McPS) for abdominal tenderness
Day 0	2.36 ± 1.43	2.36 ± 1.43	0.43
Days 11–14	1.06 ± 1.36	1.96 ± 1.28	0.01
Day 45	0.33 ± 0.76a	1.93 ± 1.24b	<0.0001

Data presented were as follows: mean ± SD; ^ap < 0.0001 considered extremely significant on Day 11 and Day 30 from Day 0 in the Acacia group. ^bp > 0.05 considered not significant on days 11–14 and Day 45 from Day 0 in the placebo group; tests used were as follows: Wilcoxon matched paired test VAS : visual analogue scale; LAP : lower abdominal pain; LBA : low backache.